$112.63
▼ $-0.30
(-0.27%)
Vol 501K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$4.6B
ROE
-179.0%
D/E
273.80
Beta
0.37
52W
$8–$113
Wall Street Consensus
17 analysts · Apr 20267
Strong Buy
8
Buy
2
Hold
0
Sell
0
Strong Sell
88.2%
Buy Rating
Price Chart
Similar Stocks
CGON
CG Oncology Inc
$3.3B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
PTCT
PTC Therapeutics Inc
P/E 8.1
$6.1B
ERAS
Erasca Inc
$1.1B
CAI
Caris Life Sciences Inc
$7.6B
TGTX
TG Therapeutics Inc
P/E 10.6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70.7
$3.2B
IMVT
Immunovant Inc
$5.1B
APGE
Apogee Therapeutics Inc
$5.2B
DNTH
Dianthus Therapeutics Inc
$1.8B
Earnings
Beat rate: 60.0%
Next Report
May 12, 2026
EPS Estimate: $-1.04
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.04 | — | — |
| Dec 2025 | $-1.06 | $-0.97 | +$0.09 |
| Sep 2025 | $-1.03 | $-0.92 | +$0.11 |
| Jun 2025 | $-0.90 | $-1.04 | $-0.14 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -150.2% | -96.2% | -150.1% | -150.1% | -150.2% | -179.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 223.72 | 113.68 | 223.72 | 223.72 | 273.80 | 273.80 |
| Current Ratio | 4.58 | 6.61 | 4.58 | 4.58 | 12.26 | 12.26 |
Key Ratios
ROA (TTM)
-58.0%
P/B
4.2
EPS (TTM)
$-3.67
CF/Share
$-2.73
52W High
$112.64
52W Low
$7.58
$7.58
52-Week Range
$112.64
How does CELC compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CELC valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
4.2
▲
71%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CELC profitability vs Biotechnology peers
ROE
-179.0%
▼
166%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-58.0%
▼
24%
below
peers
(-46.7%)
vs Peers
vs Industry
Below avg
CELC financial health vs Biotechnology peers
D/E ratio
273.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
12.3
▲
176%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.4
▼
62%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CELC fundamentals radar
CELC
Peer median
Industry
CELC profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CELC vs peers: key metrics
Latest News
No related news yet